Morphic Holding, Inc.

MORF

US61775R1059

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
31.83 ^USD	+1.76%		-6.41%	+10.21%

Jul. 01	Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000 Growth Index	CI
Jul. 01	Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 2000 Growth Index	CI

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 2500 Growth Index

July 30, 2024

Latest news about Morphic Holding, Inc.

Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000 Growth Index	Jun. 30	CI
Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 2000 Growth Index	Jun. 30	CI
Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 2500 Growth Index	Jun. 30	CI
Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Morphic Holding, Inc.(NasdaqGM:MORF) dropped from Russell 3000E Growth Index	Jun. 30	CI
Crystal Amber's Portfolio Company Wins US Regulatory Nod for Diabetes Device Study Amendment	Jun. 04	MT
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule A4ß7 Inhibition of Gut-Trafficking Cells	May. 21	CI
Morphic Holding, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Morphic Holding Names Simon Cooper as Chief Medical Officer	Mar. 19	MT
Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer	Mar. 19	CI
Morphic Holding's Full Year 2023 Net Loss Widens, Collaboration Revenue Falls	Feb. 22	MT
Morphic Holding, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
North American Morning Briefing : Stock Futures -2-	Feb. 21	DJ
Transcript : Morphic Holding, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
Morphic Ethical Equities Fund Buys Back Shares	Dec. 27	MT
Citigroup Starts Morphic Holding With Buy Rating, $46 Price Target	Dec. 08	MT
RBC Cuts Price Target on Morphic Holding to $76 From $80, Keeps Outperform, Speculative Risk	Nov. 06	MT
Morphic Holding, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03	CI
Morphic Holding, Inc. Announces Chief Executive Officer Changes	Nov. 03	CI
Transcript : Morphic Holding, Inc. - Special Call	23-10-12
BMO Capital Lowers Price Target on Morphic to $52 From $106, Maintains Outperform Rating	23-09-28	MT
North American Morning Briefing : Stock Futures Helped by Retreating Bond Yields	23-09-27	DJ
Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence	23-09-26	CI
Morphic Chief Executive to Take Medical Leave of Absence; Shares Slump After Hours	23-09-26	MT
North American Morning Briefing : Yield Surge -2-	23-09-26	DJ

Morphic Holding, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Companyâs Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The Company is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). It has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Morphic Holding, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.83 USD

Average target price

56 USD

Spread / Average Target

+75.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHIC HOLDING, INC.	+10.21%	1.59B
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+42.66%	40.03B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research